Moderna has shipped the first vials of its coronavirus vaccine candidate, mRNA-1273, to the Institute of Allergy and Infectious Diseases (NIAID).
NIAID will use the product for an upcoming Phase I clinical trial in the US. NIAID official said that the trial is due to start in April, reported Wall Stree Journal.
MRNA-1273 is an mRNA vaccine that encodes for a prefusion stabilised form of the Spike (S) protein of the coronavirus. The candidate was chosen by Moderna in alliance with the NIAID Vaccine Research Center (VRC).
The Coalition for Epidemic Preparedness Innovations (CEPI) funded the production of this batch. mRNA-1273 was delivered from the company’s manufacturing plant in Norwood, Massachusetts, US.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Moderna chief technical operations and quality officer Juan Andres said: “The collaboration across Moderna, with NIAID, and with CEPI has allowed us to deliver a clinical batch in 42 days from sequence identification.
“This would not have been possible without our Norwood manufacturing site, which uses leading-edge technology to enable flexible operations and ensure high-quality standards are met for clinical-grade material.”
The coronavirus vaccine candidate is part of the Moderna’s core prophylactic vaccines modality.